Opendata, web and dolomites

Fucoderm

An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Fucoderm project word cloud

Explore the words cloud of the Fucoderm project. It provides you a very rough idea of what is the project "Fucoderm" about.

sufferers    ingredient    pharma    commercial    chronic    life    inflammatory    itchy    preferences    historically    characterised    topical    treatment    active    attributes    convenience    dermatitis    record    drug    biotechnology    toxicity    dominated    brown    first    glycomar    seaweed    unpleasant    steroid    successful    dilutive    pursuit    rashes    launch    lesions    treatments    team    periods    reaching    generative    creams    responds    steroids    discovery    comprise    2019    attracting    collective    profitability    quality    atopic    cash    marine    market    mild    track    grant    severe    extensive       disease    4b    pharmaceutical    fucoidan    maintenance    healthcare    eczema    formulation    commercialisation    fucoderm    glycobiology    shortcomings    expertise    turn    adults    tend    pipeline    ad    child    skin    saccharides       natural    consumers    created    prescription    opting    reticent    extracted    cosmetic    company    negative    90    nutraceutical    moderate    immunomodulatory    maximising    create    meet   

Project "Fucoderm" data sheet

The following table provides information about the project.

Coordinator
GLYCOMAR LIMITED 

Organization address
address: DUNSTAFFNAGE MARINE LABOARATORY EUROPEAN CENTRE FOR MARINE BIOTECHNOLOGY DUNBEG ARGYLL
city: OBAN
postcode: PA37 1QA
website: www.glycomar.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.glycomar.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCOMAR LIMITED UK (OBAN) coordinator 50˙000.00

Map

 Project objective

Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of life. Treatment has historically been dominated by topical steroid creams, although consumers – reticent to using steroids over long periods, and for convenience (some steroid treatments are prescription only) – are increasingly opting for non-pharma products with natural attributes. These natural products, however, tend to have high toxicity and therefore to create unpleasant side effects. Glycomar’s eczema treatment, Fucoderm, directly addresses these shortcomings and responds to consumer preferences. Using an active pharmaceutical ingredient extracted from brown seaweed – a Fucoidan – Glycomar has created a novel topical formulation for maintenance treatment. The product is the first commercial application of Glycomar’s extensive glycobiology expertise – the team has over 100 years’ collective experience in marine biotechnology and drug discovery/development – and it will be targeted towards mild- to moderate AD sufferers. Together these cases comprise 80-90% of the €4b market, which is growing at 3,8% – maximising potential impact. The company, which has been working for 10 years in pursuit of novel immunomodulatory saccharides, has a track record of attracting non-dilutive grant funding, and of creating cash generative, value enhancing partnerships. Successful commercialisation of Fucoderm would enable Glycomar to meet its target of reaching profitability by 2019, in turn facilitating the launch of other consumer healthcare, nutraceutical and cosmetic products in the development pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUCODERM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUCODERM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More